Zacks Research upgraded shares of Medicenna Therapeutics (OTCMKTS:MDNAF – Free Report) from a hold rating to a strong-buy rating in a research report released on Monday,Zacks.com reports.
Medicenna Therapeutics Price Performance
MDNAF opened at $0.66 on Monday. Medicenna Therapeutics has a one year low of $0.57 and a one year high of $1.43.
About Medicenna Therapeutics
Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.
Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile.
Recommended Stories
- Five stocks we like better than Medicenna Therapeutics
- Trump Devises the Death of the IRS ☠️
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Wall Street Alert: Buy AES
- Bitcoin is down but your income is about to explode
- A month before the crash
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
